Calyxt Names Debra Frimerman as General Counsel
Calyxt, Inc. (NASDAQ: CLXT) a consumer-centric, food- and agriculture-focused Company, announced today the appointment of Debra Frimerman as General Counsel, effective February 11, 2019. Debra brings deep industry knowledge and legal expertise to the Calyxt executive team.
“We are pleased to welcome Debra to Calyxt at such a critical growth period for the company,” said Jim Blome, CEO of Calyxt. “She has been recognized by the industry as a highly strategic thinker, and her counsel will be truly instrumental as we navigate the commercialization of our first product, high oleic soybean oil, which will deliver on our promise of addressing American health challenges such as obesity and diabetes by making healthier food ingredients for consumers.”
Before joining Calyxt, Ms. Frimerman was Associate General Counsel for Syngenta North America, as well as acting General Counsel for Syngenta Seeds, LLC. Through her seven years at Syngenta, she provided counsel for executive leadership teams and contributed to the closing of numerous global transactions; launching new products into new markets; and developing regulatory, compliance and corporate policies. Prior to her role at Syngenta, Ms. Frimerman practiced law at Stoel Rives LLP and Lindquist & Vennum PLLP (now Ballard Spahr).
“Calyxt is pioneering the way for consumer-centric non-transgenic crops using its leading gene editing technology and technical expertise,” noted Debra Frimerman. “I am excited to join the team and help Calyxt deliver healthier food ingredients that provide benefits across the value chain – from farmers to consumers.”
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Roseville, Minnesota, and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K, and Cellectis’ Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2017 along with other Calyxt and Cellectis subsequent filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005709/en/